Johnson & Johnson (NYSE: JNJ) has a price-to-earnings ratio of 18.95x that is above its average ratio. Additionally, the 36-month beta value for JNJ is 0.54. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 8 rating it as “hold,” and 2 rating it as “sell.”
The public float for JNJ is 2.41B and currently, short sellers hold a 0.66% ratio of that float. The average trading volume of JNJ on April 22, 2024 was 7.45M shares.
JNJ) stock’s latest price update
Johnson & Johnson (NYSE: JNJ)’s stock price has soared by 1.49 in relation to previous closing price of 145.74. Nevertheless, the company has seen a gain of 0.26% in its stock price over the last five trading days. Forbes reported 2024-04-20 that An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies’ talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company’s latest legal issue involving talc products.
JNJ’s Market Performance
JNJ’s stock has risen by 0.26% in the past week, with a monthly drop of -5.04% and a quarterly drop of -8.52%. The volatility ratio for the week is 1.82% while the volatility levels for the last 30 days are 1.38% for Johnson & Johnson The simple moving average for the last 20 days is -2.87% for JNJ’s stock, with a simple moving average of -6.71% for the last 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with HSBC Securities repeating the rating for JNJ by listing it as a “Buy.” The predicted price for JNJ in the upcoming period, according to HSBC Securities is $170 based on the research report published on April 18, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $163, previously predicting the price at $170. The rating they have provided for JNJ stocks is “Equal Weight” according to the report published on December 13th, 2023.
UBS gave a rating of “Buy” to JNJ, setting the target price at $180 in the report published on December 01st of the previous year.
JNJ Trading at -5.38% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.95% of loss for the given period.
Volatility was left at 1.38%, however, over the last 30 days, the volatility rate increased by 1.82%, as shares sank -5.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.37% lower at present.
During the last 5 trading sessions, JNJ rose by +0.26%, which changed the moving average for the period of 200-days by -9.15% in comparison to the 20-day moving average, which settled at $151.89. In addition, Johnson & Johnson saw -5.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JNJ starting from Broadhurst Vanessa, who sale 8,891 shares at the price of $162.16 back on Mar 13 ’24. After this action, Broadhurst Vanessa now owns 15,043 shares of Johnson & Johnson, valued at $1,441,765 using the latest closing price.
JOHNSON & JOHNSON, the 10% Owner of Johnson & Johnson, sale 3,725 shares at $25.81 during a trade that took place back on Feb 16 ’24, which means that JOHNSON & JOHNSON is holding 4,099,575 shares at $96,142 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.7 for the gross margin
The net margin for Johnson & Johnson stands at 0.45. The total capital return value is set at 0.19. Equity return is now at value 18.57, with 7.62 for asset returns.
Based on Johnson & Johnson (JNJ), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at 0.78. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is 24.26.
Currently, EBITDA for the company is 29.34 billion with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 4.07. The receivables turnover for the company is 6.03for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.16.
Conclusion
In conclusion, Johnson & Johnson (JNJ) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
